Pfizer to acquire Allergan in US$160bn deal

25 November 2015 - Deborah Wilkes

Archived

Pfizer is set to acquire Botox maker Allergan in a deal worth US$160 billion. Allergan's Actavis global generics business – including the international OTC unit – will not be part of the transaction.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: